Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Total Liabilities (2020 - 2025)

BioAtla's Total Liabilities history spans 6 years, with the latest figure at $50.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 31.08% year-over-year to $50.0 million; the TTM value through Dec 2025 reached $50.0 million, up 31.08%, while the annual FY2025 figure was $50.0 million, 31.08% up from the prior year.
  • Total Liabilities reached $50.0 million in Q4 2025 per BCAB's latest filing, up from $47.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $56.7 million in Q3 2023 to a low of $33.2 million in Q1 2021.
  • Average Total Liabilities over 5 years is $44.3 million, with a median of $44.6 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: crashed 42.43% in 2021, then soared 31.08% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $43.6 million in 2021, then increased by 4.12% to $45.4 million in 2022, then grew by 7.91% to $49.0 million in 2023, then decreased by 22.11% to $38.2 million in 2024, then surged by 31.08% to $50.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Total Liabilities are $50.0 million (Q4 2025), $47.1 million (Q3 2025), and $43.9 million (Q2 2025).